Trial Profile
A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination With Methotrexate Therapy, in Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Otilimab (Primary) ; Folic acid; Folic acid; Folic acid; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BAROQUE
- Sponsors GlaxoSmithKline; GSK
- 15 Jun 2019 Results assessing Patient Reported Outcomes presented at the 20th Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting